The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H Gastric Cancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences
- PMID: 38960883
- PMCID: PMC11224720
- DOI: 10.5230/jgc.2024.24.e26
The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H Gastric Cancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Comment in
-
Reply: Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H Gastric Cancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences.J Gastric Cancer. 2024 Oct;24(4):353-355. doi: 10.5230/jgc.2024.24.e40. J Gastric Cancer. 2024. PMID: 39375061 Free PMC article. No abstract available.
Comment on
-
Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach.J Gastric Cancer. 2019 Mar;19(1):1-48. doi: 10.5230/jgc.2019.19.e8. Epub 2019 Mar 19. J Gastric Cancer. 2019. PMID: 30944757 Free PMC article. Review. No abstract available.
-
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach.J Gastric Cancer. 2023 Jan;23(1):3-106. doi: 10.5230/jgc.2023.23.e11. J Gastric Cancer. 2023. PMID: 36750993 Free PMC article. Review.
References
-
- Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005–1020. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical